The capacity extension is expected to provide increased manufacturing capabilities to fulfil the growing demand for prescription and consumer healthcare products including proprietary drug delivery systems
Aptar Pharma to expand capacity at Congers site in US. (Credit: AptarGroup, Inc.)
Aptar Pharma, a part of the Aptar Group, has embarked on the next phase of its global capacity expansion plan in North America by investing in its Aptar Congers site in New York, US.
The capacity extension is expected to provide increased manufacturing capabilities and capacity to fulfil the growing demand for prescription and consumer healthcare products including proprietary drug delivery systems.
At Aptar Congers, manufacturing started in 2002 with the production of Aptar Pharma’s VP3 pumps in a cleanroom. Currently, the facility produces a variety of patented medication delivery systems for injection and nasal delivery routes.
The facility’s manufacturing capabilities are expected to be significantly enhanced to provide Aptar Pharma’s North American clients with even more creative product solutions and higher production capacity.
Aptar Pharma is increasing the manufacturing capacity of its proprietary Unidose (UDS) Nasal Spray Systems with the addition of moulds and assembly lines in cleanroom manufacturing settings.
The additional capacity is scheduled to come online in Q4 2024 to support the growing patient demand for systemic nasal delivery.
Additionally, the company is expanding the production of its bag-on-vale (BOV) technology at the facility by establishing an assembly line to address the growing customer demand for nasal saline solutions in the region.
The new environmentally controlled good manufacturing practice (GMP) production facility is expected to be completely operational by early 2025.
Furthermore, Aptar Pharma plans to expand its cleanroom at the Aptar Congers site for its child-resistant senior-friendly (CRSF) closure solutions to boost manufacturing capacity and better serve local customers.
Aptar Pharma president Gael Touya said: “Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines.
“This expansion is a key step in the next phase of our global expansion program, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients.”
The building extension was previously announced as part of the pharma segment’s 2020 injectable capacity increase.
It provides 28,500ft2 of extra manufacturing footprint to improve warehousing, cleanroom, and manufacturing capabilities at the facility.
Aptar Pharma’s expansion in North America is part of the company’s broader worldwide expansion strategy which also includes new production sites in India, China, and France.